We are live on
!
Find out more
MIM
MetLife Investment Management Portfolio holdings
AUM
$19.6B
1-Year Est. Return
32.64%
This Fund
S&P 500
This Quarter
Est. Return
+8.55%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$11.4B
AUM Growth
+$476M
(+4.4%)
Cap. Flow
-$300M
Cap. Flow
% of AUM
-2.64%
Top 10 Holdings %
Top 10 Hldgs %
22.33%
Holding
2,538
New
224
Increased
309
Reduced
1,136
Closed
102
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$24.1M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$21.3M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$13.2M |
| 4 |
UiPath
PATH
|
+$10.4M |
| 5 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$4.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MPLX
MPLX
|
+$20.7M |
| 2 |
Apple
AAPL
|
+$16M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$15.6M |
| 4 |
Microsoft
MSFT
|
+$13M |
| 5 |
Williams Companies
WMB
|
+$9.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.93% |
| 2 | Financials | 13.29% |
| 3 | Healthcare | 12.64% |
| 4 | Consumer Discretionary | 11.46% |
| 5 | Industrials | 9.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
REVG
2251
DELISTED
REV Group
REVG
| $170K | ﹤0.01% |
10,851
+5,180
| +91% | +$93.8K |
|
2252
International Money Express
IMXI
$343M
| $170K | ﹤0.01% |
11,455
| – | – |
|
2253
Geron
GERN
$1.01B
| $170K | ﹤0.01% |
120,603
+67,836
| +129% | +$98.7K |
|
2254
Ouster
OUST
$3.33B
| $170K | ﹤0.01% |
+1,360
| New | +$145K |
|
2255
Aligos Therapeutics
ALGS
$43.7M
| $169K | ﹤0.01% |
+332
| New | +$212K |
|
|
RRD
2256
DELISTED
RR Donnelley & Sons Co.
RRD
| $169K | ﹤0.01% |
+26,953
| New | +$147K |
|
2257
SFL Corp
SFL
$1.57B
| $168K | ﹤0.01% |
22,020
-14,574
| -40% | -$119K |
|
2258
Grid Dynamics Holdings
GDYN
$632M
| $168K | ﹤0.01% |
11,178
+7,629
| +215% | +$120K |
|
2259
CuriosityStream
CURI
$166M
| $168K | ﹤0.01% |
+12,309
| New | +$159K |
|
2260
AgEagle Aerial Systems
UAVS
$55.5M
| $167K | ﹤0.01% |
+32
| New | +$175K |
|
2261
Oric Pharmaceuticals
ORIC
$1.43B
| $167K | ﹤0.01% |
9,451
| – | – |
|
|
EVLO
2262
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $167K | ﹤0.01% |
+608
| New | +$153K |
|
2263
Babcock & Wilcox
BW
$1.46B
| $167K | ﹤0.01% |
+21,174
| New | +$175K |
|
|
VIRX
2264
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $167K | ﹤0.01% |
+14,707
| New | +$148K |
|
2265
FRP Holdings
FRPH
$425M
| $167K | ﹤0.01% |
5,986
| – | – |
|
2266
Alto Ingredients
ALTO
$315M
| $166K | ﹤0.01% |
+27,235
| New | +$158K |
|
|
IMDX
2267
Insight Molecular Diagnostics
IMDX
$147M
| $166K | ﹤0.01% |
1,448
+1,361
| +1,564% | +$133K |
|
2268
CytomX Therapeutics
CTMX
$760M
| $165K | ﹤0.01% |
26,108
+20,846
| +396% | +$162K |
|
2269
Viking Therapeutics
VKTX
$3.97B
| $165K | ﹤0.01% |
27,522
+18,376
| +201% | +$109K |
|
|
AWH
2270
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $165K | ﹤0.01% |
1,954
+798
| +69% | +$68.6K |
|
2271
Waterstone Financial
WSBF
$378M
| $164K | ﹤0.01% |
8,351
+3,044
| +57% | +$61.2K |
|
2272
GCM Grosvenor
GCMG
$841M
| $164K | ﹤0.01% |
+15,754
| New | +$186K |
|
2273
Treace Medical Concepts
TMCI
$309M
| $164K | ﹤0.01% |
+5,245
| New | +$167K |
|
2274
Evolus
EOLS
$536M
| $164K | ﹤0.01% |
+12,941
| New | +$142K |
|
2275
Titan International
TWI
$450M
| $164K | ﹤0.01% |
+19,291
| New | +$188K |
|
Similar funds
SPIA
BG
PCM
CS
HHII
LF
EIM
MetLife Investment Management's Q2 2021 Portfolio in Review
As of Q2 2021, MetLife Investment Management held 2,538 positions worth $11.4B, up 4.4% from $10.9B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
MetLife Investment Management's Q2 2021 filing shows 224 new, 309 increased, 1,136 reduced and 102 closed positions. Its largest new stake was UiPath: 142,126 shares worth $9.65M. The largest sale was MPLX, an estimated $20.7M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- MetLife Investment Management's largest Q2 2021 buy was UiPath: 142,126 shares worth $9.65M.
- MetLife Investment Management added most to State Street SPDR S&P 500 ETF Trust in Q2 2021, an estimated $24.1M increase.
- MetLife Investment Management's biggest Q2 2021 reduction was Apple, cutting an estimated $16M.
- MetLife Investment Management fully exited MPLX in Q2 2021, selling an estimated $20.7M.
- MetLife Investment Management's ten largest holdings make up 22% of its $11.4B portfolio in Q2 2021.
- MetLife Investment Management opened 224 new positions and closed 102 in Q2 2021.
- MetLife Investment Management's portfolio value rose 4.4% quarter-over-quarter to $11.4B.
Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.